Conclusion
In conclusion, the 12 SQ tree SLIT-tablet was well tolerated in tree
pollen allergic subjects with no major safety concerns detected. The
majority of the most frequently reported IMP-related AEs were local
allergic reactions primarily in the oral cavity and throat. They
resolved without treatment, and they were mild or moderate in severity
with the onset of the most frequently reported local reactions on day 1.
This safety profile supports daily at-home sublingual administration
once the first dose is tolerated when administered under medical
supervision. Additional studies should investigate the long-term safety
and tolerability of the SQ tree SLIT-tablet.